# Eculizumab For the Acute Attack of Neuromyelitis Optica Spectrum Disorder

> **NCT07184840** · PHASE2 · RECRUITING · sponsor: **Tianjin Medical University General Hospital** · enrollment: 110 (estimated)

## Conditions studied

- Neuromyelitis Optica Spectrum Disorder Attack

## Interventions

- **DRUG:** Intravenous Methylprednisolone (IVMP)
- **DRUG:** Complement protein C5 inhibitor

## Key facts

- **NCT ID:** NCT07184840
- **Lead sponsor:** Tianjin Medical University General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-09
- **Primary completion:** 2026-08-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2025-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07184840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07184840, "Eculizumab For the Acute Attack of Neuromyelitis Optica Spectrum Disorder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07184840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*